TrialLancet (London, England)2019

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Hertzel C Gerstein et al.PubMed ↗Publisher ↗

No numbers read from the abstract.